Fission products from nuclear reactors are released into the environment in gaseous form. Radioactive iodine isotopes can be inhaled and accumulate in the thyroid gland, potentially causing thyroid disorders. The highest risk is to fetuses and children. In 1996, the Secretary of State for Health decided to implement the distribution of iodine tablets to people living within a 10-kilometer radius of nuclear sites. In April 1997, a circular outlined the procedures for making stable iodine available to the public. At that time, since stable iodine had obtained marketing authorization, it could only be dispensed at pharmacies. Following the relaunch, the count of vouchers collected by pharmacists indicated that approximately 50% of households had picked up their supplies. The steering group, considering this result disappointing, decided to conduct a survey of a sample of the population to more accurately assess the percentage of iodine tablets collected by the population within the area covered by the specific intervention plan.